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Technical advance

Molecularly targeted nanocarriers deliver the
cytolytic peptide melittin specifically to tumor
cells in mice, reducing tumor growth
Neelesh R. Soman,1 Steven L. Baldwin,2 Grace Hu,2 Jon N. Marsh,2 Gregory M. Lanza,1,2
John E. Heuser,3 Jeffrey M. Arbeit,4 Samuel A. Wickline,1,2,3 and Paul H. Schlesinger3
1Department

of Biomedical Engineering, 2Department of Medicine, 3Department of Cell Biology and Physiology, and
of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
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The in vivo application of cytolytic peptides for cancer therapeutics is hampered by toxicity, nonspecificity,
and degradation. We previously developed a specific strategy to synthesize a nanoscale delivery vehicle for
cytolytic peptides by incorporating the nonspecific amphipathic cytolytic peptide melittin into the outer lipid
monolayer of a perfluorocarbon nanoparticle. Here, we have demonstrated that the favorable pharmacokinetics of this nanocarrier allows accumulation of melittin in murine tumors in vivo and a dramatic reduction in
tumor growth without any apparent signs of toxicity. Furthermore, direct assays demonstrated that molecularly targeted nanocarriers selectively delivered melittin to multiple tumor targets, including endothelial and
cancer cells, through a hemifusion mechanism. In cells, this hemifusion and transfer process did not disrupt
the surface membrane but did trigger apoptosis and in animals caused regression of precancerous dysplastic
lesions. Collectively, these data suggest that the ability to restrain the wide-spectrum lytic potential of a potent
cytolytic peptide in a nanovehicle, combined with the flexibility of passive or active molecular targeting, represents an innovative molecular design for chemotherapy with broad-spectrum cytolytic peptides for the treatment of cancer at multiple stages.
Introduction
Host defense peptides are a class of small amphipathic peptides
(10–50 aa) found in most eukaryotic cells that serve diverse functions in humans and other species stemming from their antibiotic, anticancer, and antiinflammatory properties (1–5). These peptides rapidly associate with phospholipid cell membranes, move
laterally in the membranes, and oligomerize, thereby leading to
structural defects (e.g., pores) in the cell membrane. Alternatively,
after intracellular transport, they act in a similar way on the membranes of internal organelles, inducing biochemical changes that
cause cell death. Many groups have explored the unique potential
of naturally occurring and synthetic peptides for cancer chemotherapy. By covalently fusing the membrane-active peptides with
receptor-targeted peptide motifs, it has been possible to achieve
very specific targeting to particular tumors for highly cytotoxic
peptides (6–9). We now propose and demonstrate a nanoemulsion-peptide complex based on observations that certain of these
membrane-active peptides would not be susceptible to traditional
mechanisms of cancer resistance and that combination therapy
with cytolytic peptides and standard chemotherapeutic drugs
might be synergistic (10–12). This construct addresses the potentially serious off-target toxicity of the membrane-active peptides
when delivered i.v. while providing a suitable delivery agent that
resists destruction by the peptide itself that could complicate systemic application of these and similar agents.
Melittin exemplifies this large class of membrane-active peptides
that manifest membrane-disrupting activity when incorporated into
traditional bilayer delivery systems (i.e., liposomes) (13, 14). MelitConflict of interest: Samuel A. Wickline and Gregory M. Lanza have ownership,
stock options, and consultant relationships with Kereos Inc.
Citation for this article: J. Clin. Invest. 119:2830–2842 (2009). doi:10.1172/JCI38842.
2830

The Journal of Clinical Investigation

tin is a water-soluble cationic amphipathic 26-aa α-helical peptide
derived from the venom of the honeybee Apis mellifera (14). It is a very
nonspecific cytolytic peptide that attacks all lipid membranes, leading to significant toxicity when injected i.v., thereby precluding any
meaningful therapeutic benefit (4). The basis of melittin’s action is
a physical and chemical disruption of membrane structure resulting in profound compromise of the cell permeability barrier by lysis
(14–17). The peptide partitions into the cell membranes as a monomer, followed by oligomerization into toroidal or barrel stave structures that facilitate pore formation to effect cell death (17, 18).
By analogy to nature’s own delivery mechanism for such potent
toxins, we sought to achieve a practical therapeutic application by
designing a synthetic delivery vehicle that would serve as a protected peptide storage platform sufficiently stable to deliver the
melittin by either “passive” accumulation using endothelial permeability and retention or “active” delivery by selective molecular
recognition to either advanced or preclinical tumors through a
direct delivery mechanism that actuates melittin function upon
contact with the cell membrane by extension of itself into the
target. Pharmacological requirements for such a delivery vehicle
would include suitable pharmacokinetic properties indicative of
avoidance of rapid destruction by proteolysis and cell-selective targeting and lack of significant off-target toxicity (e.g., hemolysis).
Pharmacodynamic challenges include consideration of cellular
trafficking and intracellular disposition following delivery. Process challenges would include the need to preserve the complex
peptide/protein structure throughout the formulation process,
which is required to retain biological activity.
In this study, we report what we believe is a new paradigm for targeted delivery of this and other problematic classes of cell-penetrating peptides to kill cancer cells both in vitro and in vivo. We have
recently described technical details of a perfluorocarbon nanoemul-

http://www.jci.org

Volume 119

Number 9

September 2009

Downloaded on August 23, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/38842

technical advance

Figure 1
Synthesis of melittin-loaded nanoparticles and their interactions with red blood cells and cancer cells. (A) TEM of liposomes and perfluorocarbon
nanoparticles before and after incorporation of melittin (lipid/melittin molar ratio, 40). Note the disruption of liposomes and the stable insertion
of melittin into nanoparticles. Also shown are the freeze-fracture transmission electron micrographs of the hemifusion between a lipid monolayered nanoparticle and bilayered liposome. Scale bars: 200 nm. (B) Melittin-loaded nanoparticles (melittin NP) display reduced lysis of red
blood cells. A standard hemolysis assay was performed on fresh umbilical cord blood (see Methods). Free melittin is highly lytic to red cells with
an IC50 of 0.51 μM. (C) Melittin-loaded nanoparticles kill cancer cells. A 12-hour B16F10 melanoma cell proliferation was determined by MTT
assay. Incorporation of melittin onto nanoemulsions produces a 7-fold protection from free peptide (IC50 of 0.7 μM for free melittin vs 5.1 μM for
nanoemulsions). Data are represented as mean ± SD.

sion vesicle that appears capable of serving as a selectively targeted
carrier that remains stable after insertion of melittin, which might
serve to deliver the melittin in vivo (19). Our nanovehicle carriers are
synthesized as an oil-in-water emulsion composed of a liquid perfluorooctyl bromide (PFOB) core having a monolayer of phospholipid
forming a stabilizing interface with the aqueous media (20–24). We
have illustrated the stable incorporation of melittin into the outer
lipid monolayer of these nanovehicles by surface plasmon resonance, fluorescence, and circular dichroism spectroscopy (19).
We now demonstrate for what we believe is the first time the ability to safely deliver significant payloads of melittin i.v. and to target
and kill 3 types of experimental tumors: syngeneic (B16F10 mouse
melanoma); xenograft (MDA-MB-435 human breast cancer); and
precancerous lesions in K14-HPV16 mice with squamous dysplasia and carcinoma. Furthermore, we illustrate the flexibility of this
approach in both actively and passively targeted applications in
vivo, characterize the unique fusion-based delivery mechanism of
these nanovehicles, which avoids endosomal sequestration, and
demonstrate favorable mechanistic dependencies on cancer cell
membrane cholesterol content and apoptotic burden for induction of tumor cell–specific apoptotic cell death.
The Journal of Clinical Investigation

Results
Melittin-loaded nanoparticle synthesis and action on cancer cells in vitro.
The chemical synthesis of melittin-loaded nanoparticle complexes has been described earlier (19). When melittin is incorporated
into the nanoparticle’s stabilizing outer lipid monolayer, it produces no detectable alteration in the basic nanoparticle structure.
In contrast, melittin completely destroys liposomal carriers by
membrane disruption through pore formation (Figure 1A). In the
perfluorocarbon nanoparticles, melittin situates in the covering
lipid monolayer due to immiscibility in the hydrophobic-lipophobic perfluorocarbon core. The mean hydrodynamic nanoemulsion diameter is approximately 227 nm by dynamic light scattering (range 100 nm to 400 nm). The lipid/melittin molar ratio on
the nanoemulsions can be varied from 3000 to 40 by adjusting
the ratio of melittin and nanoemulsions during the formation
of the complex as described in Methods. The dissociation constant for the binding of melittin to the lipid membrane of the
nanoparticles as determined by surface plasmon resonance (SPR)
experiments is 3.27 nM. SPR experiments also show that the dissociation of melittin from the nanoparticles exhibits 3 distinct
phases. The dissociation half-life for the prolonged slow-release
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Figure 2
Pharmacokinetics and biodistribution of melittin-loaded nanoparticles. (A)
The clearance of 1 mg/kg Tc-labeled melittin injected i.v. (either free or
on nanoparticles) from circulation (n = 3). A 2-compartment biexponential model was fit to the data. Note the rapid elimination of free melittin
and the prolonged circulation of melittin-loaded nanoparticles (elimination
time ≈ 330 minutes). (B) The biodistribution of 1 mg/kg Tc-labeled melittin
injected i.v. (either free or on nanoparticles) after 2 hours (n = 3–4). Most
of the free Tc-labeled melittin is in the spleen, liver, and lungs.

final phase is greater than 100 hours (19). This permitted us to
prepare nanoemulsion-melittin complexes with the amount of
bound peptide indicated in the figures.
The interaction of nanoparticles with liposomes was investigated
by freeze-fracture platinum replica electron microscopy. The fracture plane is clearly visible in the liposome and crosses onto the
nanoparticle lipid monolayer (Figure 1A). The continuous fusion
membrane thus formed can allow the movement of lipids and peptides such as melittin from the nanoparticle to the liposome.
To confirm the protection against off-target cell toxicity afforded by the melittin-loaded nanoparticles, red blood cell hemolysis
assays were conducted in vitro. Soluble free melittin rapidly lyses
red cells, which is a major source of in vivo toxicity and serves as
a standard test of melittin’s bioeffects. Incorporation of melittin
on the nanoparticles increased the IC50 (concentration that causes
50% hemolysis) from 0.51 ± 0.12 μM for free melittin to greater
than 10 μM for nanoemulsions (Figure 1B). Even a concentration
of 25 μM nanoparticle melittin only elicited 10% hemolysis.
When tested in vitro as a cancer cell therapeutic in a 12-hour
cell proliferation (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide [MTT]) assay, free melittin was highly toxic to
B16F10 melanoma cells (IC50: 0.75 ± 0.19 μM). However, when
incorporated on the nanoparticle, the IC50 was 5.1 ± 1.2 μM, which
reflects the slow release of melittin from the nanoparticles (Figure
1C). This reduction of nonspecific melittin lytic activity is expected
to render the nanoparticles much less toxic than free melittin after
systemic administration.
Melittin-loaded nanoparticle safety and pharmacokinetic profiling
in vivo. To evaluate the benefits of incorporating melittin into a
nanostructure for safe and effective peptide delivery in vivo, we
first performed pharmacokinetic and biodistribution studies. Tclabeled melittin was injected i.v. (either free or in nanoparticles)
into C57BL/6 mice, blood collected at various time points, and the
distribution in various organs quantified after 2 hours. The plasma half-life for free melittin was 0.79 ± 0.05 minutes (distribution
2832
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phase) and 24.36 ± 4.75 minutes (elimination phase), with a volume
of distribution of 9.32 ± 1.54 ml (Figure 2A), which was significantly
larger than the total mouse blood volume (85–100 ml/kg). Within
10 minutes, the blood concentration of free melittin was reduced
to 1% of the injected dose per gram, and at 2 hours, most of the free
melittin was sequestered in the spleen, liver, and lungs (Figure 2, A
and B). As expected from prior reports (15, 25), the free melittin rapidly inserted into the red cell membranes, producing severe damage
and hemolysis, followed by removal through filtration organs.
In dramatic contrast, the in vivo clearance of melittin-loaded
nanoparticles exhibited a typical biexponential decay. The initial
distribution phase (t1/2 = 4.22 ± 1.48 minutes) was followed by a
markedly prolonged elimination phase (t1/2 = 329.45 ± 78.89 minutes) as compared with free melittin. The volume of distribution
was 2.94 ± 0.31 ml. In light of the stark differences in pharmacokinetic parameters, a 10-fold increase in the amount of melittin
circulating in the blood 2 hours after injection was a consequence
of its incorporation into the nanoparticles (Figure 2B).
To define the in vivo safety profile, melittin-loaded nanoparticles
were injected i.v. at 13.5 mg/kg (equivalent dose of melittin) every
third day for a total of 7 doses in 4-month-old FVB/N mice. Even
though the LD50 of free melittin after i.v. injection is 3–4 mg/kg (26),
no significant changes in the levels of serum enzymes or electrolytes
were observed that might otherwise suggest damage to major organs
(Table 1) after injection of melittin-loaded nanoparticles. Since the
values for serum enzymes may vary among laboratories depending
on the method of analysis, the mice treated with saline served as
a valid internal control in our studies. In any case, the laboratory
values for the saline-treated mice were well within the range of previously published data (27). Also, routine tissue histology on liver,
lung, kidney, and heart revealed no evidence of tissue damage (data
not shown). Tests for free hemoglobin in the urine with urine strips
(Vetstrip; ARJ Medical) revealed no evidence of hemolysis.
Melittin-loaded nanoparticle suppression of tumor growth in vivo by EPR.
The accumulation of drug-delivery vehicles in solid tumors by the
endothelial permeability and retention effect (EPR) is well documented and is the dominant mechanism of action for the therapeutic effect of the FDA-approved compounds Doxil and Abraxane (28,
29). Because this approach is simple and acceptable to regulatory
agencies as a form of therapy, we first sought to demonstrate the
therapeutic utility of melittin-loaded nanoparticles against tumor
growth through the conventional EPR mechanism.
We tested the efficacy of melittin-loaded nanoparticles against
xenograft MDA-MB-435 human breast cancers in athymic nude
mice. Matrigel and 2 million MDA-MB-435 human breast cancer
cells stimulated by 100 ng/ml VEGF and basic FGF (bFGF) were
implanted s.c. in the right inguinal fat pad. The mice were treated i.v.
starting at day 7 after implant with either saline, nanoparticles, or
melittin-loaded nanoparticles (2.5 mg/kg) every third day for a total
of 5 doses. The tumors were imaged by ultrasound to calculate the
tumor volume at the beginning (day 7) and end (day 22) of the treatment. The melittin-loaded nanoparticles significantly inhibited the
growth of the tumors by 24.68% ± 1.57% as compared with the saline
controls and 27.16% ± 2.9% as compared with the nanoparticle controls (n = 6; P < 0.05, Kruskal-Wallis test and post hoc Mann-Whitney U test). Interestingly, in this xenograft model, αvβ3 integrin–targeted melittin-loaded nanoparticles given in a regimen similar to
that of the nontargeted melittin-loaded nanoparticles resulted in
an equivalent (22.72% ± 3.1%) decrease in the tumor growth rate as
compared with the saline controls (data not shown).

http://www.jci.org

Volume 119

Number 9

September 2009

Downloaded on August 23, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/38842

technical advance

Figure 3
Therapeutic efficacy of melittin-loaded nanoparticles in syngeneic B16F10 mouse melanoma tumors. (A) Graph showing the increase in tumor
volume of B16F10 melanoma tumors during the course of treatment with melittin-loaded nanoparticles (8.5 mg/kg) or controls (saline or nanoparticles alone; n = 5 each group). Note the dramatic difference in tumor volume at day 14 after 4 doses of melittin-loaded nanoparticles. Data
are represented as mean ± SD. **P < 0.01. (B) Histological assessment of B16F10 melanoma tumors excised at day 14. Note the extensive
nonproliferating dead areas in the treated tumors along with the markedly decreased vascularity. Arrows indicate blood vessels in the H&E and
CD31 photographs and dead areas in the BrdU photographs.

Given the prominent role played by the immune system in effecting tumor regression (30), we also evaluated the efficacy of melittinloaded nanoparticles in immunocompetent mice. Syngeneic B16F10
mouse melanoma tumors implanted s.c. in C57BL/6 mice actively
secrete angiogenic growth factors and have already developed a
vascular supply by day 5 (31). A dramatic reduction of melanoma
growth (Figure 3A) was observed after 4 i.v. injections of melittinloaded nanoparticles every other day starting at day 5 (8.5 mg/kg
per dose). The final tumor weight on day 14 was 0.23 ± 0.19 g
(n = 5; P <0.01, Kruskal-Wallis test and post hoc Mann-Whitney
U test) for the treated mice compared with 1.87 ± 0.86 g for the
saline controls (or ~88% reduction in tumor mass) and 1.80 ± 0.69 g
for the mice given nanoparticles alone without melittin (~87%
reduction). Histology revealed a decrease in the number of blood
vessels (CD31 staining), a decrease in proliferating cells, and significant areas of necrosis in the melittin-loaded nanoparticle–treated
tumors that were not present in saline controls (H&E) (Figure 3B).
This histological result is consistent with tumor-trapped melittin-loaded nanoparticles directly producing tumor cell death. We
also determined tumor growth suppression at an injected dose of
1 mg/kg (below the LD for injection of free melittin). This reduced
tumor weight to 0.92 ± 0.23 g (n = 5; P < 0.05, Mann-Whitney U test)
compared with 1.92 ± 0.64 g for vehicle alone (~52% reduction in
tumor mass). This permitted a direct comparison with the biodistribution data below.
Regarding the safety profile in a cancer model, no toxic effects
were apparent in terms of the organ weights or serum chemistry
profiles. Serum hemoglobin levels were demonstrably and significantly higher (P < 0.05, Mann-Whitney U test) in melittin-loaded
The Journal of Clinical Investigation

nanoparticle–treated mice (12.78 ± 1.32 gm%, where gm% indicates gm per 100 ml) as compared with the saline-treated controls (10.58 ± 1.46 gm%). The liver enzyme aspartate transaminase
(AST) was significantly lower (P < 0.05, Mann-Whitney U test) in
melittin-loaded nanoparticle–treated mice (329 ± 162 U/l) than in
saline-treated controls bearing tumors (2097 ± 1162 U/l). Because
elevated levels of AST commonly accompany liver metastases, the
lower levels in the treated mice are consistent with inhibition of
liver metastases (32, 33), although this remains to be proved.
We observed that biodistribution and effectiveness are closely
linked with noncovalent incorporation into nanoemulsions. Using
Tc-labeled melittin, we observed a dramatic concentration of melittin persisting in the tumor at 4 hours and 24 hours after injection. At a dose that resulted in an approximately 88% reduction in
tumor growth rate (8.5 mg/kg melittin-loaded nanoparticles) the
in-tumor retention was 2.55 ± 0.85 μg/g. At lower injected doses of
1 mg/kg, we directly demonstrated that the tumor accumulation
of melittin from the melittin-loaded nanoparticles was 6.5-fold
increased as compared with 1 mg/kg free melittin injection. This
produced the 52% tumor size reduction indicated above. Perhaps
the tumor growth would also be suppressed by injecting higher
doses of free melittin but exceeding the LD for injected melittin,
which is 3–4 mg/kg (26), would result in loss of the test animals.
It is for this precise reason that free melittin (or likely other cytolytic peptides in general) would not be able to elicit a therapeutic
benefit at a safe dose. The enhanced tumor accumulation from
melittin-loaded nanoparticles compares favorably with the 10-fold
tumor increase reported for liposomal Doxil (29) and surpasses
the 33% increase reported for Abraxane (28).
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Figure 4
Delivery of melittin from integrin αvβ3–targeted nanoparticles to endothelial cells and cancer cells. (A and B) A 5-fold reduction in IC50 after specific targeting of melittin-loaded nanoparticles to endothelial cells and melanoma cells. 3-hour cell proliferation was determined by the MTT assay
(see Methods). Incorporation of melittin onto nanoparticles produces a 25-fold protection from free peptide (IC50 of 1–2 μM for free melittin and
greater than 25 μM for nontargeted nanoparticles). Specific targeting of the nanoparticles to αvβ3 integrins produces a 5-fold enhancement of
melittin toxicity; IC50, 6–8 μM. Data are represented as mean ± SD. (C and D) A typical permanganate-fixed transmission picture (left) and platinum replica images (right) of C32 melanoma cells interacting with either nontargeted (C) or αvβ3 integrin–targeted nanoparticles (D). (E) Selected
higher magnification platinum replica images of nanoparticles on the plasma membrane and microvilli of C32 melanoma cells. Left 2 panels show
nontargeted nanoparticles, and the right 2 panels show αvβ3 integrin–targeted nanoparticles attached to microvilli. Scale bars: 200 nm.

Development and characterization of molecularly guided nanoparticles.
Although nanoparticles are effective as cargo vehicles to deliver
the melittin to established tumors by EPR, we sought to determine
whether specific molecular targeting of the nanoparticles to neovascular targets would be useful in treating nascent early-stage
tumors or precancerous lesions that are just entering an aggressive angiogenic phase. Such a strategy could be useful for early
treatment of emerging lesions while further limiting exposure to
off-target tissues to minimize side effects. The experimental plan
entailed in vitro characterization of the formulation to confirm
targeting ability followed by in vivo application against precancerous lesions in genetically engineered mice.
Human melanoma (C32) cells that express the α vβ 3 integrin were used in vitro to assess the interactions of targeted
nanoparticles with cell membranes by surface plasmon resonance. Nanoparticles were targeted by incorporating a peptido2834
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mimetic αvβ3 integrin–binding ligand (a highly specific vitronectin antagonist at 200 copies per nanoparticle) as previously
described (34–36). The avidity is high due to multiple binding
events so that off rates are very slow (37).
Biacore L1 chip surfaces were loaded with nanoparticles with or
without the αvβ3 peptidomimetic ligand at 0.1mole% (where mole%
is calculated as [moles of ligand]/[moles of total lipids in nanoemulsion] × 100). The binding response of the C32 cells increased
6-fold: from 82.3 ± 10.1 RU for nontargeted nanoparticles to
461.7 ± 51.9 RU for αvβ3 integrin–targeted nanoparticles.
To confirm the therapeutic activity of the targeted melittinloaded nanoparticles against potential tissue targets, the proliferation of mouse endothelial (2F2B) cells and human melanoma
(C32) cells in culture was tested. The soluble free melittin IC50
in this proliferation assay on cultured cells was 0.93 ± 0.26 μM
for C32 cells and 2.21 ± 1.08 μM for 2F2B cells (Figure 4, A and
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Figure 5
Release of cytochrome c (cyt c) and induction of apoptosis by αvβ3 integrin–targeted melittin-loaded nanoparticles. (A) Effect of αvβ3 targeting
on the association of fluorescein-melittin with C32 melanoma cells in culture visualized by confocal microscopy. Cells were exposed to fluorescein-melittin at 37°C. Scale bar: 20 μm. (B) A single C32 melanoma cell reconstruction using the T3D package in NEOSYS. This allows viewing
both the cell surface and intracellular distribution of the fluorescein-melittin after incubation at 37°C. (C) C32 melanoma cells were treated with
the indicated concentration of melittin on αvβ3 integrin–targeted nanoparticles. Apoptosis was determined by flow cytometry. Cells stained with
annexin V–FITC only were considered early in apoptosis and those stained with annexin V–FITC and 7-AAD were late apoptotic cells. Data
are represented as mean ± SD. n = 3. (D) Comparison of cytochrome c release from mitochondria and extracellular release of LDH. Data are
represented as mean ± SD. n = 3. *P < 0.05; **P < 0.01.

B). When the cells were exposed to nontargeted melittin-loaded
nanoparticles, a substantial decrease in melittin lytic activity was
observed, analogous to that demonstrated above for hemolysis:
IC50 was 32.3 ± 3.9 μM for C32 cells and 28.9 ± 4.33 for 2F2B
cells. This level of protection against off-target damage was consistent with the concentration of lytic particles and proved that
dissociation of melittin from the nanoparticles was minimal during the period of culture (3 hours). By including αvβ3 integrin
mimetic on the nanoparticles, the interaction of nanoparticles
with cells was increased 4-fold. This increase in cell nanoparticle
interaction resulted in a reduction of the IC50 for inhibition of
cell proliferation to 6.8 ± 2.14 μM for C32 cells and 8.39 ± 2.35
for 2F2B cells. Thus, the increased binding of the nanoparticles
to the cells accounts for the increased activity of the targeted
nanoparticles. Since the nanoparticles themselves do not cause
any deleterious effects on the cells (38, 39), by using them as
nanocarriers, we attenuated nonspecific cellular lysis that is characteristic of soluble (free) melittin and simultaneously enabled
selective targeting of the nanoparticles to endothelial and cancer
cells and restored the lytic potential of melittin in proportion
to the extent of cell-nanoparticle interaction. The activity of the
targeted melittin-loaded nanoparticle complex closely approxiThe Journal of Clinical Investigation

mates the lytic activity of free melittin but now is restricted to the
cancer and endothelial cells that express the integrin.
An interesting and unique form of interaction between the
nanoparticles and the targeted cells became apparent through
these studies. Transmission electron microscopy (TEM) was used
to confirm the role of the receptor-ligand targeting to enhance
interactions of αvβ3 integrin–targeted nanoparticles with cells. In
the absence of the targeting peptidomimetic, very few nanoparticles were associated with the surface membrane of the cells (Figure
4C). However, when the targeted nanoparticles were presented to
the cells, large numbers were associated with microvilli and also
extended to the membrane surface (Figure 4D). Yet no evidence
of direct cellular membrane disruption or endocytosis of particles
was observed even in the presence of melittin. Furthermore, after
7 minutes of warming to 37°C, there was no intracellular accumulation of intact whole nanoparticles in the thin sections stained
with permanganate. These and other related studies with model
bilayer systems (i.e., liposomes; Figure 1A) suggest that cell-surface
contact and nanoparticle-cell membrane interactions offer a direct
pathway for cargo transport from the nanoparticle (Figure 4E). By
way of explanation, the amphiphile stabilizing layer allows the formation of a hemifusion pathway between the lipid monolayer of the
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Table 1
Safety evaluation of melittin-loaded nanoparticles
Test

Hemoglobin (gm%)
Alanine transaminase (U/l)
AST (U/l)
Alkaline Phosphatase (U/l)
Creatinine kinase (U/l)
Blood urea nitrogen (mg%)
Glucose (mg%)
Amylase (U/l)
Albumin (gm%)
Creatinine (mg%)
Bilirubin (mg%)
Potassium (mmol/l)
Chloride (mmol/l)
Sodium (mmol/l)

Saline injected
(mean ± SD)
11.62 ± 0.62
73.4 ± 18.63
62.5 ± 15.3
35.8 ± 8.56
152.2 ± 110.9
18.8 ± 2.28
160.4 ± 17.99
6116 ± 1877
2.26 ± 0.23
0.4 ± 0.05
0.1 ± 0.02
6.56 ± 0.7
105 ± 6.36
138.8 ± 6.45

Melittin NP
injectedA
(mean ± SD)
11.7 ± 0.72
69.8 ± 11.12
82.25 ± 14.84
54.4 ± 12.89
138.4 ± 49.18
21.8 ± 3.11
147 ± 12.8
5806 ± 2366
2.16 ± 0.25
0.4 ± 0.03
0.1 ± 0.01
7.67 ± 0.96
106.8 ± 11.12
138.5 ± 6.95

AAfter

i.v. injection of 7 doses of melittin-loaded nanoparticles (13.5 mg/kg
melittin) over 24 days.

nanoparticle and the bilayer of the cell that leads to the delivery of
peptide cargo driven by a combination of surface tension, chemical potential, and Marangoni effects (40). This pathway is quite
distinct from conventional mechanisms for liposome or nanoparticle delivery across membranes, which alternatively must proceed
through vehicle endocytosis and/or disruption of the cell-surface
membrane and subsequent endosomal processing to release cargo
from endosomal compartments.
To further elucidate the targeted delivery mechanism, we
labeled melittin with fluorescein and examined the trafficking of the peptide (1 μM) delivered from nanoparticles to cells.
Confocal micrographs of targeted C32 melanoma cells demonstrate internalization of fluorescein-melittin transferred from
αvβ3 integrin–targeted and nontargeted nanoparticles to cells,
which confirms the importance of the targeting strategy for
rapid and direct cytoplasmic peptide delivery (Figure 5A). After
incubation at 37°C for 1 hour with the nanoparticles, a uniform
cell membrane fluorescence was observed along with a diffuse
intracellular fluorescence. Z-plane reconstructions of the cellular
image with the T3D package in NOEsys (Research Systems Inc.)
demonstrated the heavy labeling of the microvillus cell surface
of these cells and the accumulation of FITC-labeled melittin (but
not intact nanoparticles) in endocytic vesicles (Figure 5B). The
specific internalization of the membrane-bound melittin was
confirmed by cooling to 4°C or by ATP depletion, both of which
led to a dramatic reduction of intracellular endosomal fluorescence (data not shown), thereby demonstrating an energy dependence for the movement of melittin after it has been delivered to
the cell surface from the targeted nanoparticles.
Targeted melittin-loaded nanoparticles induce cell death by apoptosis.
Flow cytometry analysis of annexin V–FITC binding and 7-aminoactinomycin D (7-AAD) nuclear staining was used to assess
the contribution of apoptotic versus necrotic cellular death after
the interaction with targeted melittin-loaded nanoparticles. A
dose-dependent decrease was observed in the percentage of viable
cells after incubation with αvβ3 integrin–targeted melittin-loaded
2836
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nanoparticles. The cell death was explained by the observed dosedependent increase in early and late apoptotic cells (Figure 5C).
We did not observe necrosis in these cell cultures with melittin
concentrations of 12.5 μM, which is 2 times the IC50 for cell death,
meaning that when more than 95% of the cells were dying, there
was no detectable necrosis from melittin-loaded nanoparticles.
To determine whether the nanoparticle-delivered melittin elicited apoptosis after trafficking to intracellular membranes via
activation of the intrinsic pathway, we measured the intracellular
release of cytochrome c. To delineate the role of intracellular membrane disruption versus cell-surface membrane lysis, we also determined the release of lactate dehydrogenase (LDH) from cultured
C32 melanoma cells. This approach allowed us to directly compare
the functional integrity of these 2 groups of cellular membranes
after the delivery of the melittin peptide to the cellular surface
membrane from targeted nanoparticles. Cells treated with 0.1%
Triton X-100 or 10 μM camptothecin were assumed as standards
for 100% release of LDH or cytochrome c release, respectively. The
cells treated with targeted melittin-loaded nanoparticles released
cytochrome c from their mitochondria and exhibited a concentration-dependent increase of apoptosis (Figure 5D). However, there
were small releases of LDH after treatment with 2.5 μM (11% ± 5%)
or 12.5 μM (17% ± 3%) αvβ3 integrin–targeted melittin-loaded
nanoparticles. The corresponding release of cytochrome c was
23.5% ± 4.3% and 37.2% ± 6.1%, respectively, which was significantly higher than in the control cells (P < 0.05). Thus, the cellular
release of LDH did not increase to the same extent as the release
of cytochrome c, while the fraction of apoptotic cells progressively
increased. This mechanistic distinction was maintained up to
a dose of melittin that achieved 92% cell death by apoptosis. In
contrast, the free melittin doses that produced necrotic cell death
generated the expected concomitant release of both cytochrome c
and LDH. At a concentration of 1 μM soluble melittin, 19.17% ± 4.2%
LDH release was observed, while 68.14% ± 7.1% release was observed
at 5 μM. This release was significantly higher than that for the control cells (P < 0.05). Thus, a 5-fold increase of free melittin dramatically accelerated the release of LDH while the same fold increase
of targeted nanoemulsions increased the LDH release by a much
smaller amount (Figure 5D). Our data demonstrate a clear distinction between the effects of melittin delivered to the cell surface
by nanoparticles and the activity of soluble (free) melittin. Even
at high concentrations, melittin delivered to the cell surface from
nanoparticles drives cellular apoptosis and does not produce the
necrotic cell death that is induced by soluble melittin.
These data suggest that melittin is being internalized by an
active process after the cell-surface delivery by the nanoparticles.
Yet considerable melittin also remained on the cell surface, where
its pore-forming activity was held in check by some mechanism.
Because cholesterol in the cell membrane along with sphingolipids
promotes tight packing of the acyl chains (41), we anticipated that
cholesterol in the plasma membrane of C32 cells might inhibit
local pore formation, which would in turn reduce cell necrosis. And
because cancer cells may harbor greater levels of membrane cholesterol than do normal cells in order to reduce apoptosis (42–44),
we surmised that depletion of cholesterol might alter the mode of
cell death. To evaluate this hypothesis, we depleted the cell plasma
membrane cholesterol to identify the cause of cellular mortality
in response to targeted melittin-loaded nanoparticles. The effectiveness of this treatment was determined directly by cholesterol
assay on the treated cells. Modest reductions of cell membrane
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Figure 6
Role of cholesterol in the induction of apoptotic cell death by αvβ3 integrin–targeted melittin-loaded nanoparticles. (A) C32 melanoma cells were
treated with 2 concentrations of methyl-β-cyclodextrin (MBCD) to remove cholesterol as described in Methods and in Results. These cells were
washed and exposed to the αvβ3 integrin–targeted nanoparticles. After incubation in culture, cell proliferation was determined by MTT assay
as described in Methods. Data are represented as mean ± SD. **P < 0.01. (B–G) Cells treated as described in A were stained with annexin V–
FITC and 7-AAD before analysis by cell sorting after treatment with the nanoparticles: (B) nanoparticles; (C) 2.5 μM αvβ3 integrin-targeted
melittin-loaded nanoparticles; (D) 0.25 mM MBCD; (E) 0.5 mM MBCD; (F) 0.25 mM MBCD and 2.5 μM αvβ3 integrin–targeted melittin-loaded
nanoparticles; and (G) 0.5 mM MBCD and 2.5 μM αvβ3 integrin–targeted melittin-loaded nanoparticles. Cells stained with annexin V–FITC were
considered early in apoptosis, and those stained with 7-AAD also were late apoptotic cells. Numbers show the percentage of cells in the respective quadrants. (H) Schematic depiction of interaction of C32 melanoma cells with αvβ3 integrin–targeted melittin-loaded nanoparticles.

cholesterol, 7% at 0.25 mM or 12% at 0.5 mM methyl-β-cyclodextrin, produced no untoward effects on cell proliferation (Figure
6A). However, the cholesterol-depleted cells displayed a decrease in
proliferation when exposed to targeted melittin-loaded nanoparticles (Figure 6A). Flow cytometry indicated that the removal of
approximately 13% of cellular cholesterol before treatment with
2.5 μM melittin on αvβ3 integrin–targeted nanoparticles yielded
inanimate cell debris, consistent with a completely necrotic mode
of cell death (Figure 6, B–G).
Based on these data, we hypothesized that the melittin traffics to
the mitochondrial membrane and thereby causes membrane disruption by pore formation and cytochrome c leakage, eventuating in
apoptotic cell death. As shown in Figure 6H, the nanoparticles were
stabilized by a monolayer of lecithin and contained adsorbed melittin. The αvβ3 peptidomimetic was bound to the integrin on the cell
membrane surface, a bilayer normally containing 40% cholesterol.
The close approximation of these 2 lipid layers leads to the formation of hemifusion stalk. This provides a pathway for the movement
of lecithin and melittin to move to the cell surface driven by Marangoni flows. In the high cholesterol membrane, melittin is unable
to form pores but through endocytosis moves to the intracellular
membranes like late endosomes, endoplasmic reticulum, and mitoThe Journal of Clinical Investigation

chondrial outer membrane, all of which have low cholesterol content. Melittin is able to form pores in these intracellular compartment membranes, leading to apoptotic cell death. When cholesterol
is reduced at the cell surface, melittin-induced pores compromise
the osmotic control of the cell, leading to necrosis.
Safe regression of precancerous lesions in vivo with targeted melittinloaded nanoparticles. The K14-HPV16 mouse model is an example
of a genetically engineered model of squamous carcinoma harboring human papilloma virus (HPV) transgenic elements (E6 and
E7 oncogenes) driven by a keratin promoter. These mice progress
from hyperkeratosis (1 month) to acanthosis and papillomatosis (4 to 5 months) and finally to epidermal carcinoma (7 to 12
months). Angiogenesis is abundantly observed near the basement
membrane between the dermis and epidermis during the precancerous dysplastic stage and persists in invasive squamous cancers
(45). Overexpression of integrin αvβ3 receptors on endothelial
cells is a hallmark of angiogenesis in this and other tumor models.
We visualized and compared the binding of rhodamine-labeled
nanoparticles (nontargeted and αvβ3 targeted) in the ears of
4-month-old transgenic mice by fluorescence microscopy. As seen
in the overlay pictures (Figure 7A), the ears of mice injected with
αvβ3 integrin–targeted rhodamine nanoparticles showed extensive
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Figure 7
Regression of precancerous epidermal dysplatic lesions in the ears of K14-HPV16 mice by αvβ3 integrin–targeted melittin-loaded nanoparticles.
(A) Fluorescence microscopy pictures of mouse ear sections showing the extensive overlay with FITC-lectin (shown by arrows) of αvβ3 integrin–targeted rhodamine-nanoparticles compared with nontargeted ones. (B) Representative H&E-stained pictures of K14-HPV16 mouse ear
sections after treatment with 7 doses of melittin-loaded nanoparticles (melittin dose, 13 mg/kg). Note the regression of papillae (shown by arrows)
in the group treated with αvβ3 integrin–targeted melittin-loaded nanoparticles. Scale bars: 100 μm (C) Chart showing the specific effect of targeted
melittin-loaded nanoparticles on regression of severe papillae (greater than 100 μm). Data are represented as mean ± SEM. n = 5. *P < 0.05.

areas of overlap between rhodamine and fluorescein (vasculature)
as compared with the ears of mice injected with nontargeted rhodamine nanoparticles.
We evaluated the therapeutic effect of αvβ3 integrin–targeted
melittin-loaded nanoparticles that were hypothesized to exert a
dual antiangiogenic and antitumor action on the ear epidermal
papillae. The efficacy of the targeted therapeutic in vivo was demonstrated by a quantitative reduction in dermal papillae, which are
the site of the genetically driven dysplastic changes (Figure 7, B and
C). After 7 i.v. doses of nanoparticles every third day, each containing an equivalent melittin amount of 13.5 mg/kg, the treatment
effects were analyzed. As shown in Figure 6H, counts of papillae
(mean ± SEM) that exceeded 100 μm in height per cm in the ear
epidermis of the saline-treated and nontargeted melittin-loaded
nanoparticle groups numbered 5.86 ± 1.84 and 5.82 ± 1.97, respectively. In contrast, for the mice treated with αvβ3 integrin–targeted
melittin-loaded nanoparticles, the papillae count was 1.14 ± 0.70
(n = 5; P < 0.05, Kruskal-Wallis test and post hoc Mann-Whitney
U test), representing an 80% reduction in severe dysplastic lesion
prevalence. No apparent organ toxicity was observed after all treatments, as indicated by unchanged blood chemistry profiles.
Discussion
In designing our synthetic nanoscale delivery vehicle for melittin,
we sought to limit the off-target membrane lytic activity of this
peptide without having to alter its native structure by mutagenesis
or fusion to achieve that result (4, 46). We further anticipated that
2838
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this approach might be useful for many membrane-active peptides.
The LD for free melittin when injected i.v. is 3 to 4 mg/kg (26). In
contrast with melittin delivered from nanoparticles, free melittin
rapidly inserts into the red cell membranes after i.v. administration. At high doses, this causes massive hemolysis and acute renal
failure (47) and at low doses, subtle changes in red cell rigidity (48).
In any case, the rigid, deformed, or lysed red blood cells are rapidly
eliminated from the circulation by the spleen, liver, and lungs. The
absence of any apparent toxicity of melittin-loaded nanoparticles
after injection of an equivalent dose that is 4 times the LD of free
melittin points to the effective shield that the nanoparticle lipid
monolayer provides against the cytotoxic effects of melittin.
Incorporation of melittin onto the nanoparticles prolongs the
melittin circulation time, thereby offering an increased stochastic
probability of accumulation in the tumor and targeted binding
to sites of angiogenesis. The random collisions that nanoparticles
encounter with different cell types in the vasculature (i.e., red and
white blood cells, endothelial cells) might trigger the formation of
a hemifusion complex and subsequent delivery of small amounts
of melittin to the cells during their prolonged serum residence
times compared with free melittin (Figure 2A and Figure 4E).
However, this delivery of melittin is small and produces a striking decrease in nonspecific hemolysis attributable to the use of
nanoparticles as compared with free melittin and is critical to the
therapeutic potential of this delivery paradigm (Figure 1B). Fortuitously, circulating nanoparticles that do not reach their targets are
accumulated and deactivated in the liver and spleen, while those
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that do reach their targets by virtue of favorable pharmacokinetics
still deliver a sufficient melittin payload to have an effect on control of cancer cells that carry a specific apoptotic burden (49, 50).
The demonstrated efficacy of both nontargeted and αvβ3 integrin–targeted melittin-loaded nanoparticles indicates that the melittin-loaded nanoparticles could exert their antitumor effect either by
nonspecific trapping in the abnormal tumor vasculature or binding to overexpressed integrins on angiogenic endothelial cells (36).
Since murine tumors are leakier than human tumors, it is unclear
at this point whether the nontargeted and/or the αvβ3 integrin–targeted melittin-loaded nanoparticles would be more efficacious in a
clinical setting. However, the antiangiogenic effect of melittin-loaded nanoparticles that triggers apoptosis in the target cell could be
advantageous for treatment of early cancerous lesions, as demonstrated from the regression of papillae within epidermal dysplastic
lesions in transgenic K14-HPV16 mice. The broad applicability of
the melittin nanoparticle construct is evident in 3 distinct tumor
lines employed for in vivo work: the B16F10 syngeneic in immunocompetent C57BL/6 mice, the human MDA-MB-435 xenograft in
athymic nude (NCr-nu/nu) mice, and the K14-HPV16 transgenic
in FVB/N mice. Each offers an opportunity to evaluate the melittin effect against a varied tumor background and immune state to
abnegate model (animal/tumor) dependency effects. In each case,
efficacy is clearly demonstrable regardless of immune state, tumor
type, animal background, or mechanism of nanoparticle interaction with the tumor (EPR vs. targeted delivery).
Regarding safety of these formulations, it has been shown recently that doxorubicin-loaded nanoparticles targeted to integrin αvβ3
do not cause any renal damage in preclinical mouse models (51). In
previous published studies using αvβ3 integrin–targeted fumagillin perfluorocarbon nanoparticles, we found no perceptible kidney
damage in rabbits (36). Also, perfluorocarbon-lecithin emulsions
have already been approved for clinical use as blood substitutes
(Perflubron). Furthermore, integrin antibodies and peptibodies
have proved safe in phase 1 and 2 clinical trials (52–57). Thus,
we do not anticipate toxicities from these 2 components of the
nanoparticulate system. Moreover, we observe a dramatic lack of
toxicity with melittin-loaded nanoparticles in our mouse studies
in terms of changes in serum electrolytes, serum enzymes, or body
weights even after repeated injections (total 7) at doses 4 times the
LD of free melittin. Parenthetically, melittin is a weak allergen as
compared with the various other constituents in bee venom, and
despite the presentation of the melittin-carrying structures to the
macrophage phagocytic system, melittin has not been shown to
induce an immune response in bee keepers (58–60), likely due to
its small size and rapid inactivation via peptidases in vivo.
The integrin receptor is widely expressed, but only in minute
quantities in normal tissues as compared with tumor neovasculature (61–63), which was recently pointed out again by the Cheresh
group, who first described the role of this epitope in tumor vasculature (51). It is expected that during wound healing and in any
tissues that are undergoing active angiogenesis, such as spermatic
cords, cartilage growth plates, and uterine and ovarian tissues, the
endothelial integrin will be expressed during the early active phase
of the process, but we anticipate that nanoparticle interactions
with these tissues would be no more deleterious for melittin than
for any other chemotherapeutic agent that is designed to interdict
rapidly growing tissue types. As demonstrated by our preliminary
toxicity data, this approach has produced a safe and effective complex for harnessing the anticancer and/or antiangiogenic activity
The Journal of Clinical Investigation

of a potent cytolytic peptide such as melittin, which previously
has been achieved by the design and synthesis of unique surrogate
peptides (4). It is likely that this nanoparticulate delivery system
might find a useful and safe application for these peptides also as
well as other naturally occurring host defense peptides.
The interaction of molecularly targeted nanoparticles with cells
(Figure 4, C and D) differs dramatically from that of other typical biovehicles (e.g., liposomes, polymeric nanoparticles) in that it
does not seem to require endocytosis of the intact carrier complex
(64, 65). Specific targeting to cancer cells by the incorporation of
mimetic targeting ligands leads to the binding, close apposition,
and hemifusion of the lipid monolayer with the targeted cell lipid
membrane (Figure 4E). Lipids and peptides such as melittin that
are inserted in the nanoparticle monolayer can then diffuse along
the continuous hemifusion pore, becoming part of the target cell
membrane (Figure 6H). Entry into the cell appears to be by endocytosis of the cellular membrane to which the cargo has been transferred (22). We demonstrate that the contact-mediated transfer of
melittin by nanoparticles produces cytochrome c release and apoptosis. Previously, cellular apoptosis from melittin exposure of cells
has been attributed to calcium entry or activation of phospholipase A2 (66, 67). The details of the nanoparticle mechanism of
melittin delivery remain to be revealed, but the exclusive apoptotic
cell destruction suggests that the cell-surface membrane remains
intact and that intracellular membranes are being disrupted.
To conclude, we have demonstrated that synthetic nanoscale
vehicles such as perfluorocarbon nanoparticles can deliver a potent
model cytolytic peptide (melittin) by flexible passive and active
molecular targeting to kill both established solid tumors and precancerous lesions. The biocompatibility of liquid fluorocarbons
is well documented from their application in liquid ventilation,
oxygen delivery, and imaging (68–71). Even at large doses, most
fluorocarbons are innocuous and physiologically inactive. Perfluorocarbon nanoparticles thus represent the first in a class of unique
lipid-based delivery vehicles for melittin and other such cytolytic
peptides with broad spectrum and multimodal antivascular and
antitumor actions that could be exploited for anticancer therapy.
Methods
Synthesis of perfluorocarbon nanoparticles. Perfluorocarbon nanoparticles were
synthesized as an oil-in-water emulsion by microfluidization as described
earlier (72). The lipid surfactant used consisted of egg lecithin (98 mole%)
and dipalmitoyl-phosphatidylethanolamine (DPPE) (2 mole%) (Avanti Polar
Lipids Inc.). αvβ3 integrin–targeted nanoparticles were made by incorporating 0.1 mole% peptidomimetic vitronectin antagonist (US Patent 6,322,770)
conjugated to polyethylene glycol 2000–phosphatidylethanolamine (PEG
2000–phosphatidylethanolamine) (Avanti Polar Lipids Inc.), replacing
equimolar quantities of lecithin. The effective binding affinity for the αvβ3
integrin per particle is approximately 50 pM, as reported recently by our
group, due to multiple simultaneous ligand binding (23). The specificity for
αvβ3 integrin as compared with glycoprotein IIb/IIIa (GP IIbIIIa) receptor is
more than 3 orders of magnitude in binding affinity (34).
Incorporation of melittin onto the nanoparticles. Melittin-loaded nanoparticles
were formulated by mixing known amounts of melittin to perfluorocarbon
nanoparticles. Pure melittin peptide was produced by solid-state peptide
synthesis and was obtained from Robert Mecham (Department of Cell Biology and Physiology, Washington University School of Medicine). The melittin was dissolved in 100 mM KCl (pH 7, 10 mM HEPES) at 0.1 mM, and 2
to 20 μl was added to 25 μl of nanoparticle suspension with mixing. After
incubation at room temperature for 10 minutes, the nanoparticles were
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washed twice by centrifugation (100 g, 10 minutes) to remove the unbound
melittin. The melittin in the supernatant was quantified by measuring the
tryptophan fluorescence (excitation, 280 nm; emission, 350 nm). Depending on the amount of melittin added, the melittin-loaded nanoparticles
yielded molar lipid/melittin ratios ranging from 3000 to 40. For animal
studies and except where otherwise noted, the lipid/melittin ratio was 40.
Preparation of liposomes. To compare the behavior of traditional liposomes
to the proposed perfluorocarbon nanoparticle vehicles as peptide carriers, liposomes (98 mole% egg lecithin, 2 mole% DPPE) were synthesized as
described earlier (73).
Electron microscopy. The effect of melittin on bilayered liposomes and on
monolayered perfluorocarbon nanoparticles was examined by TEM. The
nanoparticles were sequentially stained with 1.25% osmium tetroxide, 2%
tannic acid, and uranyl acetate, after which the pellet was dehydrated and
embedded in Poly/Bed 812 (Polysciences Inc.). The negative stained pellet
was then thin-sectioned on a Reichert-Jung Ultracut, and after placing on
copper grids, was viewed on a Zeiss 902 electron microscope.
Replicating and imaging deep-etched or freeze-dried samples. The interaction
of C32 melanoma cells with either nontargeted or αvβ3 integrin–targeted
nanoparticles was studied by centrifuging a suspension of nanoemulsions
on a plate of melanoma cells, followed by warming for 7 minutes at 37°C
to allow nanoparticle fusion/uptake, a process referred to as spinoculation
(74). The samples were deep-etched and fractured at 105°C. After sequential platinum replication, 1% potassium permanganate fixation, and rotary replication, the samples were transferred to Formvar-coated grids and
viewed by TEM at 100 kV (74).
Hemolysis assay. Human umbilical cord blood was obtained from healthy
donors after informed consent. The red cells were separated, and various
concentrations of melittin or melittin-loaded nanoparticles were added to
a fixed number of red cells (5 × 10 cells) and incubated at 37°C for 3 hours.
The release of hemoglobin was quantified by measuring the absorbance at
540 nm of the supernatant in a Microplate Reader (model 550; Bio-Rad)
after centrifugation. The absorbance of the supernatant obtained by incubating the red cells in water under identical conditions was set to 100%.
Pharmacokinetics and biodistribution of nanoparticles. For pharmacokinetic
and biodistribution studies, melittin was chemically conjugated with Tc.
Freshly eluted TcO (13.5 mCi) was added to the Isolink Kit (Mallinckrodt
Institute of Radiology, Washington University) and heated at 100°C for
20 minutes to form the Tc tricarbonyl precursor. Melittin was added to the
precursor and incubated at 55°C for 30 minutes to allow transchelation.
The conjugation efficiency was determined by thin-layer chromatography
and was consistently greater than 95%.
Tc-labeled melittin (free or on nanoparticles) was injected i.v. through
the tail vein (1 mg/kg) in C57BL/6 mice and the blood drawn from the
jugular vein at various times. At the end of 2 hours, the mice were sacrificed and the organs removed. The radioactivity was measured in a gamma
counter (Wizard 1480; PerkinElmer). The pharmacokinetic data were fit
by a sum of exponentials model using MATLAB to calculate the volume of
distribution and the elimination half-lives.
Therapeutic efficacy of melittin-loaded nanoparticles in solid tumors. All animal
protocols were approved by the Washington University Animal Studies
Committee. Mice were housed in standard 9 × 15 × 6–inch mouse cages (3–5
per cage) and were fed with rodent chow and water. Six-week-old athymic
nude mice (National Cancer Institute) were implanted in the right inguinal
fat pad with a cocktail of 2 million MDA-MB-435 cells (50 μl), Matrigel (50 μl),
VEGF (100 ng/ml), and bFGF (100 ng/ml). At day 7 after implantation, the
tumors were imaged by ultrasound. The mice were randomized into different groups and treated with either saline, nanoparticles, or melittin-loaded
nanoparticles (melittin dose, 1 mg/kg) every third day starting at day 7 for
a total of 5 doses. At day 22, the tumors were imaged again by ultrasound.
2840
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The tumor growth rate was measured from the ratio of the starting and
end tumor volumes for the 2 groups.
C57BL/6 mice (4 to 6 weeks old; National Cancer Institute) were
implanted s.c. in the right flank with 1 million B16F10 melanoma cells.
On day 5, the mice were randomly grouped into 3 groups and were treated
with i.v. injection of either saline, nanoparticles alone, or melittin-loaded
nanoparticles (melittin dose, 8 mg/kg or 1 mg/kg) every other day for a
total of 4 doses. The tumor dimensions were measured using a caliper.
At day 14, mice were sacrificed, blood removed for serum chemistry, and
tumors or organs excised for histology. Excluding the tumor weight,
there were no significant changes in the body weight among the 3 groups
(P = NS for saline vs. nontargeted melittin-loaded nanoparticles vs. αvβ3
integrin–targeted melittin-loaded nanoparticles).
Tumor histology. Paraffin-embedded formalin-fixed tumor sections were
stained with H&E. For immunofluorescent staining, tumor sections were
stained with anti-CD31 antibody (Blood Vessel Staining Kit, Chemicon
International; Millipore) for blood vessel counts or anti-BrdU antibody
(BrdU In-Situ Detection kit; BD Biosciences — Pharmingen) using the
manufacturer’s instructions. The positively stained cells were detected by
the DAB kit or the VIP kit (Vector Laboratories), respectively. Images were
obtained using MicroSuite imaging software, version FIVE (Olympus).
Surface plasmon resonance. Biacore X biosensor and carboxymethylated
dextran chip L1 were obtained from Biacore. A uniform lipid monolayer
on an L1 chip was created by injecting 35 μl of untargeted or αvβ3 integrin–
targeted nanoparticles (3 μl/min). Attached nanoparticles were stabilized
with 50 μM of 10 mM NaOH and exposed surface covered with 25 μl of
0.1 mg/ml BSA in PBS. C32 melanoma cells in 30 μl PBS were then injected
at a flow rate of 30 μl/min and the response recorded for 60 minutes.
Ultrasound data acquisition and analysis. A high-frequency ultrasound imaging system (Vevo 660; VisualSonics) was used to acquire backscatter data
from the mouse tumors. The system was modified to output analog radio
frequency (RF) data and associated trigger signals in order to permit digitization of the raw RF waveforms. Waveforms were digitized at 500 MHz with
an 8-bit digitizer (CS82G; GaGe) and stored for offline analysis. The transducer probe (40 MHz wobbler, 6-mm focal length, 20 Hz frame rate) was
affixed to a motorized gantry under computer control in order to enable
automated scanning of the probe across the length of the tumor. Each anesthetized animal was placed on its back on a platform beneath the probe, and
a small amount of ultrasound coupling gel was applied to the area proximal
to the tumor. The probe was positioned so that the central area of the tumor
was situated in the focal region of the transducer. RF data corresponding to
cross-sectional views of the tumor was acquired at multiple sites along the
length of the tumor, so that the entire tumor volume was interrogated. The
probe was translated laterally (perpendicularly to the swing of the wobbler)
in 100-micron steps between each scan plane acquisition.
All signal and image processing was performed with custom software
plug-ins in the open-source software package ImageJ (W. S. Rasband, NIH;
http://rsb.info.nih.gov/ij/). A sliding time gate (0.1 microsec Hamming
window) was applied to each digitized RF waveform, and the log of the
sum of the squared amplitude values within the window was calculated as
the window was translated along the entire waveform. The resulting values (representative of the mean backscattered energy at each point in the
A-line) for all waveforms in each scan plane was used to generate scaled, 2D
cross-sectional images of the tumor. Regions were drawn by hand around
the apparent tumor outline for each scan plane to obtain cross-sectional
tumor area measurements. The total tumor volume was calculated based
on these cross-sectional areas and the distance between scan planes.
Cell proliferation inhibition assay. The effect of αvβ3 integrin–targeted
melittin-loaded nanoparticles on mouse endothelial (2F2B) and human
melanoma (C32) cancer cell proliferation was determined by the MTT
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assay. C32 melanoma cells express the integrin receptor αvβ3, while mouse
endothelial cells were treated with 1 nM nicotine for 3 hours to overexpress
the integrin receptor αvβ3.
Mode of cell death. Annexin V–FITC (Sigma-Aldrich) and 7-AAD staining
solution (BD Biosciences) were used to stain the phosphatidylserine in the
outer cell membrane and nucleic acids, respectively. Cells were harvested
after 1 hour of incubation at 37°C with either nontargeted or αvβ3 integrin–targeted nanoparticles and the samples analyzed by flow cytometry.
Effect of cholesterol depletion on cellular interactions. C32 melanoma cells
were treated with either 0.25 mM or 0.5 mM methyl-β-cyclodextrin
(Sigma-Aldrich) for 15 minutes at 37°C to deplete cholesterol. Amplex
Red Cholesterol Assay Kit (Invitrogen) was used to quantify the amount
of cholesterol depleted.
Intracellular trafficking of melittin. To track the melittin being delivered to
the cells and define its localization, fluorescently labeled melittin was synthesized. FluoroTag FITC Conjugation Kit (Sigma-Aldrich) was used to
conjugate FITC to the N terminus of melittin. The unconjugated FITC
was separated using a G25 sephadex column. Fluorescein-melittin–loaded
nanoparticles were incubated with C32 melanoma cells for 1 hour at 37°C.
The cells were fixed and visualized using a Zeiss 510 confocal microscope.
Confocal Z-stack images were obtained and reconstructed using the T3D
package in NOEsys (Research Systems Inc.) to confirm the intracellular
deposition of FITC-melittin. The experiment was repeated at 4°C and after
ATP depletion that was achieved by treating the cells with 20 mM sodium
azide and 50 mM 2-deoxyglucose for 15 minutes at 37°C, respectively,
prior to addition of targeted FITC–melittin-loaded nanoparticles.
Cytochrome c release assay. C32 melanoma cells were treated with varying
concentrations of αvβ3 integrin–targeted melittin-loaded nanoparticles for
1 hour at 37°C, after which the mitochondria were isolated by using the
Mitochondrial Isolation Kit (Pierce; Thermo Scientific). The cytochrome c
present in the mitochondrial and cytosol fractions thus obtained was
assayed by using the cytochrome c ELISA kit (Invitrogen). Cells treated
with 10 μM camptothecin (overnight at 37°C) were taken as 100% release.
LDH release assay. C32 melanoma cells were either treated with free melittin or αvβ3 integrin–targeted melittin-loaded nanoparticles at various concentrations for 1 hour at 37°C and the amount of LDH released quantified
by using the kit from BioVision. Cells treated with 0.1% Triton X-100 were
taken as 100% release.
In vivo efficacy in K14-HPV16 transgenic mice. The in vivo efficacy of αvβ3
integrin–targeted nanoemulsions was tested in K14-HPV16 transgenic
mice. These mice express the E6 and E7 oncogenes from HPV type 16
controlled by the human keratin 14 promoter in the basal squamous epithelium and spontaneously develop epidermal cancers over a period of 12
months that closely mimic HPV-induced human cancers (45). K14-HPV16
(4 months old) mice were obtained from Jeffrey Arbeit at Washington University. All animal protocols were approved by the Washington University
Animal Studies Committee. Around 4 to 5 months, precancerous dysplas1. Giuliani, A., Pirri, G., and Nicoletto, S. 2007. Antimicrobial peptides: an overview of a promising class
of therapeutics. Central European J. Biol. 2:1–33.
2. Papo, N., and Shai, Y. 2005. Host defense peptides
as new weapons in cancer treatment. Cell. Mol. Life
Sci. 62:784–790.
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